Home » Stocks » Gilead Sciences

Gilead Sciences, Inc. (GILD)

Stock Price: $68.50 USD 0.32 (0.47%)
Updated Aug 14, 2020 4:00 PM EDT - Market closed
After-hours: $68.31 -0.19 (-0.28%) Aug 14, 7:59 PM

Stock Price Chart

Key Info

Market Cap 85.88B
Revenue (ttm) 22.17B
Net Income (ttm) -257.00M
Shares Out 1.25B
EPS (ttm) -0.20
PE Ratio n/a
Forward PE 10.22
Dividend $2.72
Dividend Yield 3.97%

Stock Quote

Trading Day Aug 14, 2020
Last Price $68.50
Previous Close $68.18
Change ($) 0.32
Change (%) 0.47%
Day's Open 68.09
Day's Range 68.00 - 68.82
Day's Volume 9,161,326
52-Week Range 60.89 - 85.97

More Stats

Market Cap 85.88B
Enterprise Value 91.07B
Earnings Date (est) Oct 22, 2020
Ex-Dividend Date Jun 11, 2020
Shares Outstanding 1.25B
Float 1.25B
EPS (basic) -0.23
EPS (diluted) -0.20
FCF / Share 6.98
Dividend $2.72
Dividend Yield 3.97%
Earnings Yield n/a
FCF Yield 10.20%
Payout Ratio n/a
Shares Short 22.93M
Short Ratio 2.82
Short % of Float 1.70%
Beta 0.66
PE Ratio n/a
Forward PE 10.22
P/FCF Ratio 9.80
PS Ratio 3.87
PB Ratio 4.79
Revenue 22.17B
Operating Income -961.00M
Net Income -257.00M
Free Cash Flow 8.76B
Net Cash -5.19B
Net Cash / Share -4.14
Gross Margin 80.16%
Operating Margin -4.33%
Profit Margin -1.20%
FCF Margin 39.52%
ROA 4.37%
ROE -1.40%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (30)

Buy 10
Overweight 1
Hold 17
Underweight 0
Sell 2

Analyst Consensus: Overweight

Price Target

(16.66% upside)
Current: $68.50
Target: 79.91
*Average 12-month price target from 23 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth1.46%-15.24%-14.09%-6.89%31.13%122.19%15.46%15.7%5.48%-
Gross Profit17,77417,27421,73626,12928,63321,1028,3437,2316,2616,080
Operating Income4,2878,20014,12417,63322,19315,2654,5244,0103,7903,962
Net Income5,3865,4554,62813,50118,10812,1013,0752,5922,8042,901
Shares Outstanding1,2701,2981,3071,3391,4641,5221,5291,5151,5501,712
Earnings Per Share4.224.173.519.9411.917.351.811.641.771.66
EPS Growth1.2%18.8%-64.69%-16.54%62.04%306.08%10.37%-7.34%6.63%-
Dividend Per Share2.522.282.081.841.29-----
Dividend Growth10.53%9.62%13.04%42.64%------
Operating Cash Flow9,1448,40011,89817,04721,25012,8183,1053,1953,6392,834
Capital Expenditures-825-924-590-748-747-557-190-397-132-61.88
Free Cash Flow8,3197,47611,30816,29920,50312,2612,9152,7983,5072,772
Cash & Equivalents24,35230,08925,51011,89514,60710,1282,1321,8629,9002,099
Total Debt24,59327,32233,54226,34622,05512,4046,6368,2247,6073,485
Net Cash / Debt-2412,767-8,032-14,451-7,448-2,276-4,504-6,3622,293-1,386
Book Value22,52521,38720,44218,88718,53415,42611,3709,3036,7395,864
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Gilead Sciences, Inc.
Country United States
Employees 11,800
CEO Daniel P. O'Day

Stock Information

Ticker Symbol GILD
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Unique Identifier NASDAQ: GILD
IPO Date January 22, 1992


Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a kinase inhibitor; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections. In addition, the company offers its products under the name Cayston, Emtriva, Hepsera, Sovaldi, and Tybost. Further, it develops product candidates for the treatment of viral diseases, inflammatory and fibrotic diseases, and oncology. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Galapagos NV; Second Genome; Gadeta; Carna Biosciences Inc.; Nurix Therapeutics, Inc.; Humanigen, Inc.; Kiniksa Pharmaceuticals, Ltd.; Kyverna Therapeutics, Inc.; Glympse Bio, Inc.; Renown Institute for Health Innovation; Goldfinch Bio, Inc.; Insitro, Inc.; Novo Nordisk A/S; Yuhan Corporation; Kite Pharma, Inc.; oNKo-innate Pty. Ltd.; and Roche Holding AG. The company has partnership with Arcus Biosciences, Inc. to co-develop and co-commercialize next-generation cancer immunotherapies. Gilead Sciences, Inc. was founded in 1987 and is headquartered in Foster City, California.